Business
AIM Rule 17 Notice
AIM Rule 17 Notice.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 4650O Immupharma PLC 18 August 2017 \n\n 18 August 2017\n \n \n \nImmuPharma Plc\n \nAIM Rule 17 Notice\n \n \nImmuPharma PLC (LSE:IMM), (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies (\"AIM Rules\"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:\n \nTim McCarthy, the Company's Non-executive Chairman, previously held roles on the boards of Alizyme Plc and its subsidiary Alizyme Therapeutics Ltd, both of which entered into a Creditors Voluntary Winding-up in December 2009, within 12 months of his resignation. \n \nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.\n \nEnds\n\n\n\n\nFor further information please contact:\n \n\n\n\n\nImmuPharma plc (www.immupharma.org)\n\n\n+ 44 (0) 20 7152 4080\n\n\n\n\nTim McCarthy, Chairman\n\n\n\n\n\n\n\nLisa Baderoon, Head of Investor Relations\nTwitter: @immupharma\n \n\n\n+ 44 (0) 7721 413496\n \n \n\n\n\n\nNorthland Capital Partners Limited (NOMAD & Broker)\nPatrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance\nRob Rees, Corporate Broking\n\n\n+44 (0)20 3861 6625\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\...